肾血管病变在IgA肾病中的临床意义
Clinical Significance of Renal Angiopathy in IgA Nephropathy
摘要: 目的:探讨肾血管病变在IgA肾病中的临床意义及肾血管病变的风险因素。方法:收集2017年1月至2017年8月在我院IgA确诊肾病患者的临床病理资料,根据是否发生肾血管病变将其分为肾血管病变组(renal vascular lesions group, RVL组)和非肾血管病变组(non renal vascular lesions group, NRVL组)。观察RVL和NRVL组患者的临床病理资料差异。采用多因素Logsitick分析观察影响肾血管病变的风险因素。结果:共纳入105例患者,其中RVL组59例,NRVL组47例,RVL组年龄、病程、收缩压、血肌酐、24小时尿蛋白定量、血尿酸高于NRVL组(均P < 0.05)。RVL组的血白蛋白水平、eGFR低于NRVL组。RVL组病理分级高于NRVL组(P < 0.05),RVL组炎性细胞浸润、间质纤维化、肾小管萎缩、新月体病变、肾小球硬化性病变、毛细血管襻IgA沉积和C3沉积发生率均显著高于RNVL组(P < 0.05);RVL组IgG沉积、IgM沉积发生率均低于NRVL组(P < 0.05)。多因素Logsitick分析结果显示,收缩压 > 140 mmHg、血尿酸异常、肾间质纤维化、24 h尿蛋白定量、eGFR ≤ 120 ml∙min−1∙(1.73 m2)−1是影响肾血管病变的风险因素(P < 0.05)。结论:1) IgA肾病患者具有较高的肾间质血管病变发生率,肾间质血管病变是IgA肾病的重要病理特征。2) 肾间质血管病变的IgA肾病患者临床指标和病理损害更为严重,肾间质血管病变在一定程度上有助于判定IgA肾病的严重程度和预后。3) 收缩压 > 140 mmHg、血尿酸异常、肾间质纤维化、24 h尿蛋白定量、eGFR ≤ 120 ml∙min−1∙(1.73 m2)−1是影响肾血管病变的风险因素。
Abstract: Objective: To explore the clinical significance and risk factors of renal angiopathy in IgA nephropa-thy. Methods: Clinicopathological data of patients diagnosed with IgA nephropathy in our hospital from January 2017 to August 2017 were collected, according to whether renal vascular lesions oc-curred. It is divided into renal vascular lesions group, and non renal vascular lesions group, com-paring clinical andpathological features and prognosis between the two groups. The risk factors of renal vascular disease were analyzed by multi factor logsitick analysis. Results: A total of 105 pa-tients were included. There were 59 patients in the RVL group and 47 patients in the NRVL group. Age, course of disease, systolic blood pressure, serum creatinine, 24-hour urine protein level and blood uric acid in the RVL group were higher than those in the NRVL group (P < 0.05). The serum albumin level and estimated glomerular filtration rate in RVL group were lower than those in NRVL group. The pathological grade of RVL group was higher than that of NRVL group (P < 0.05), and the incidence of inflammatory cell infiltration, interstitial fibrosis, renal tubule atrophy, crescent body lesion, glomerulosclerosis, IgA deposition and C3 deposition in RVL group was significantly higher than that in RNVL group (P < 0.05). The incidence of IgG deposition and IgM deposition in RVL group was lower than that in NRVL group (P < 0.05). Multivariate logsitick analysis showed that systolic blood pressure > 140 mmHg, abnormal blood uric acid, renal interstitial fibrosis, 24 h urine protein quantification, eGFR ≤ 120 ml∙min−1∙(1.73 m2)−1 were the risk factors for renal vascular disease (P < 0.05). Conclusion: 1) IgA nephropathy patients have a high incidence of renal interstitial vascular disease, which is an important pathological feature of IgA nephropathy. 2) The clinical and patho-logical damage of IgA nephropathy patients with renal interstitial angiopathy is more serious. Renal interstitial angiopathy is helpful to determine the severity and prognosis of IgA nephropathy to a certain extent. 3) Systolic blood pressure > 140 mmHg, blood uric acid abnormality, renal intersti-tial fibrosis, 24-hour urine protein quantification, eGFR ≤ 120 ml•min−1∙(1.73 m2)−1 are the risk fac-tors of renal vascular disease.
文章引用:胡范玲, 孙建平. 肾血管病变在IgA肾病中的临床意义[J]. 临床医学进展, 2022, 12(8): 7270-7277. https://doi.org/10.12677/ACM.2022.1281050

参考文献

[1] Sharma, A. and Hariharan, S. (2019) Octreotide Delaying the Progression of Recurrent IgA Nephropathy after Kidney Transplantation. Transplant Direct, 6, e518. [Google Scholar] [CrossRef
[2] Zand, L., Can-etta, P., Lafayette, R., et al. (2019) An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. Kidney International Reports, 5, 58-65. [Google Scholar] [CrossRef] [PubMed]
[3] 白亚君, 杜艳彬, 袁心柱, 等. 大黄酚介导TLR4/NF-κB通路对IgA肾病大鼠肾损伤和免疫反应的调控作用[J]. 四川大学学报(医学版), 2019, 50(6): 840-846.
[4] 傅槟槟, 万建新. IgA肾病肾血管病变与临床病理之间的关系[J]. 中国当代医药, 2009, 16(24): 75-77.
[5] 关欣, 郑红光. IgA肾病肾血管病变危险因素的非条件logsitick回归分析[J]. 华西医学, 2011, 26(8): 1121-1124.
[6] 中华医学会儿科学分会肾脏学组. 原发性IgA肾病诊治循证指南(2016) [J]. 中华儿科杂志, 2017, 55(9): 643-646.
[7] Lee, S.M.K., Rao, V.M., Franklin, W.A., et al. (1982) IgA Nephropathy: Morphologic Predictors of Progressive Renal Dis-ease. Human Pathology, 13, 314-322. [Google Scholar] [CrossRef
[8] 容丽萍, 姜梦婕, 莫樱, 等. Katafuchi半定量评分系统和IgA肾病牛津病理分型在儿童IgA肾病的临床应用[J]. 发育医学电子杂志, 2015(3): 145-151.
[9] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会中国医师协会高血压专业委员会, 等. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志, 2019, 24(1): 24-56.
[10] 孙明姝, 母义明, 赵家军, 等. 中国临床指南现状分析及《中国高尿酸血症与痛风诊治指南(2018)》制定介绍[J]. 中华内分泌代谢杂志, 2019, 35(3): 181-184.
[11] 李想, 张倩, 聂春迎, 等. 与原发性IgA肾病患者肾间质纤维化程度相关的因素分析[J]. 山东医药, 2019, 59(30): 78-80.
[12] Zhang, H., Jia, J., Cheng, J., et al. (2012) 1H NMR-Based Metabonomics Study on Serum of Renal Interstitial Fibrosis Rats Induced By Unilateral Ureteral Obstruction. Molecular BioSystems, 8, 595-601. [Google Scholar] [CrossRef
[13] Feiner, H.D., Cabili, S., Baldwin, D.S., Schacht, R.G. and Gallo, G.R. (1982) Intrarenal Vascular Sclerosis in IgA Nephropathy. Clinical Nephrology, 18, 183-192.
[14] 刘泽洲, 苏可, 杨定平, 等. IgA肾病伴高血压患者临床病理改变特征及预后分析[J]. 中华肾脏病杂志, 2019, 35(9): 648-654.
[15] 汪晶华, 杨洁, 刘宇, 等. 伴有高血压的IgA肾病临床表现、病理特点及高血压发生的影响因素分析[J]. 解放军医药杂志, 2016, 28(10): 73-76.
[16] 李思瓯, 尹昌浩, 张忠敏. 益肾汤配合西药治疗IgA肾病伴高血压36例[J]. 世界中医药, 2013, 8(5): 528-529.
[17] 吕天洋, 张静, 贾红彦, 等. 原发性IgA肾病并发血尿酸升高患者影响因素分析[J]. 中国实验诊断学, 2019, 23(9): 1536-1537.
[18] 张永哲, 刘大军. IgA肾病合并高尿酸血症患者临床及病理特点分析[J]. 中国中西医结合肾病杂志, 2018, 19(10): 911-913.
[19] 张永哲, 刘大军. IgA肾病合并高尿酸血症患者临床及病理特点分析[J]. 中西医结合心脑血管病杂志, 2018, 19(13): 911-913.
[20] 张函, 章晓燕, 卢泽军, 等. 吸烟对IgA肾病(IgAN)患者肾功能和肾小管间质及血管病变的影响[J]. 复旦学报(医学版), 2014, 41(3): 315-320.
[21] Cattran, D.C., Coppo, R., Cook, H.T., et al. (2009) The Oxford Classification of IgA Nephropathy: Ra-tionale, Clinicopathological Correlations, and Classification. Kidney International, 76, 534-545. [Google Scholar] [CrossRef] [PubMed]
[22] Tang, S.C., Tang, A.W., Wong, S.S., et al. (2010) Long-Term Study of Mycophenolate Mofetil Treatment in IgA Nephropathy. Kidney International, 77, 543-549. [Google Scholar] [CrossRef] [PubMed]
[23] Moorhead, J.F., Chan, M.K., El-Nahas, M., et al. (1982) Lipid Ne-phrotoxicity in Chronic Progressive Glomerular and Tubulo-Interstitial Disease. The Lancet, 2, 1309-1311. [Google Scholar] [CrossRef
[24] Tang, Z.Y., Lu, B., Hatch, E., et al. (2009) C3a Mediates Ep-ithelial-to-Mesenchymal Transition in Proteinuric Nephropathy. Journal of the American Society of Nephrology, 20, 593-603. [Google Scholar] [CrossRef
[25] Rifai, A. (2007) IgA Nephropathy: Immune Mechanisms beyond IgA Mesangial Deposition. Kidney International, 72, 239-241. [Google Scholar] [CrossRef] [PubMed]